#AgiosPharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in #sicklecell disease, causing a slump in its share price.
Agios shares slide as it abandons sickle cell candidate
Agios Pharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in sickle cell disease.
buff.ly
July 21, 2026 at 1:30 PM
#AgiosPharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in #sicklecell disease, causing a slump in its share price.
#Shares in #AgiosPharma lost nearly half their value in pre-market #trading today after it posted mixed clinical results from a phase 3 trial of its #sicklecelldisease (SCD) therapy mitapivat, sending its investors into a spin.
Agios shares slump on sickle cell disease data
Shares in Agios lost nearly half their value after it posted mixed clinical results from a phase 3 trial of its sickle cell disease therapy mitapivat.
buff.ly
November 19, 2025 at 5:00 PM
#Shares in #AgiosPharma lost nearly half their value in pre-market #trading today after it posted mixed clinical results from a phase 3 trial of its #sicklecelldisease (SCD) therapy mitapivat, sending its investors into a spin.